Grants Search Results

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant helps provide necessary resources to build an early phase clinical trial program, and increase the number of such trial enrollments.

This grant funds a Research Assistant to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Funding from the St. Baldrick's Foundation has taken two very small programs at UIC and Rush Medical Centers, merged them and brought Stroger Medical Center into the fold to forge a single entity for purposes of participation in Children's Oncology Group clinical trials. This support of necessary personnel has significantly increased clinical trial participation for patients who otherwise might not have access to them.

This grant funds a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Research Nurse to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Despite the toxic effects of current treatment for children and young adults with AML, overall survival remains poor because of recurrent leukemia. If their AML does not respond to chemotherapy after relapse, chances for survival are low. This team has identified important changes in AML that can be exploited to develop more effective and less toxic treatments using new types of drugs. The consortium focuses on showing that these pathways are needed for leukemia survival, and developing pathway-directed clinical trials to improve outcomes for this group of patients with no other treatment options. Awarded to Phoenix Children's Hospital and transferred to Fred Hutchinson Cancer Research Center. Funds administered by Fred Hutchinson Cancer Research Center.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pathway Directed Treatment for Refractory AML Consortium. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pathway Directed Treatment for Refractory AML Consortium. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pathway Directed Treatment for Refractory AML Consortium. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pathway Directed Treatment for Refractory AML Consortium. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pathway Directed Treatment for Refractory AML Consortium. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This team has identified a subset of childhood Acute Lymphoblastic Leukemia (ALL) with specific genetic abnormalities in the leukemia cells (Ph-like ALL) that has poor survival. Some Ph-like ALL patients have genetic abnormalities that make their leukemia cells sensitive to a targeted therapy (dasatinib), which has many fewer side effects than chemotherapy. This consortium is using a COG clinical trial to help identify which children should respond to dasatinib, and then will add this targeted therapy to their chemotherapy to try to improve survival. Awarded at the University of Colorado and transferred to the Children's Hospital of Philadelphia. Funds administered by the Children's Hospital of Philadelphia.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.